Amarantus Bioscience Holdings Inc (AMBS)

[a surfer]

- Presentation and Webcast on May 28, 2015, at 9:00 a.m. EDT -

SAN FRANCISCO and GENEVA, May 26, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that it will be presenting at the Fourth Annual SeeThru Equity Microcap Investor Conference being held May 28, 2015, at Convene Grand Central, New York, NY.

Gerald E. Commissiong, President & CEO of Amarantus, will provide a corporate overview and an update on the clinical development of the Company's lead therapeutic product candidate eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), on Thursday, May 28, 2015, at 9:00 a.m. Eastern Time.

A live webcast of the presentation may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. The webcast replay will be available approximately two hours after the presentation ends and will be archived for 30 days.

About the Fourth Annual SeeThru Equity Microcap Investor Conference

SeeThru Equity is the premier and unbiased provider of microcap equity research and institutional and high net worth investor focused conferences. Since its inception in 2011, the firm has grown to over 125 companies under coverage and has successfully hosted 14 investor conferences. The Fourth Annual Microcap Investor Conference brings together over 60 presenting companies and 600 attendees. The conference offers detailed presentations, targeted one-on-one meetings and numerous networking opportunities.